ecancer
ecancer is a UK charity which provides accessible, high-quality educational content, free to the global oncology community. Our mission is to raise the standards of care for cancer patients across the world through education.
ESMO 2022
ecancer
ESMO 2022: Highlights, Commentary, and Analysis of the Key Studies
FEATURING
Bishal Gyawali
- 490 views
- October 3, 2022
- 2
ecancer
ESMO 2022 on the Latest in PARP Inhibitors for Metastatic Prostate Cancer
- 81 views
- September 30, 2022
ecancer
ESMO 2022 on the Phase 3 KEYNOTE-412 Study: Pembro With CRT vs. Placebo + CRT for Locally Advanced HNSCC
FEATURING
Jean-Pascal Machiels
- 60 views
- September 30, 2022
ecancer
ESMO 2022 on the New Data for Multi-Cancer Early Detection
FEATURING
Tomasz Beer
- 64 views
- September 30, 2022
ecancer
ESMO 2022 on the PATHFINDER Study: A New Era of Early Cancer Detection With Blood Test May Change Cancer Screening Paradigms
FEATURING
Deborah Schrag
- 1,118 views
- September 30, 2022
- 5
ecancer
ESMO 2022 on the Phase 3 RATIONALE-301 Study: Tislelizumab OS Benefit vs. Sorafenib as 1L Treatment for Unresectable HCC
FEATURING
Richard S. Finn
- 38 views
- September 30, 2022
ecancer
ESMO 2022 on the Phase 3 LEAP-002 Study: Lenvatinib Remains Standard of Care for 1L Therapy in Advanced HCC
FEATURING
Richard S. Finn
- 50 views
- September 30, 2022
ecancer
ESMO 2022: Fruquintinib Provides Improvement in Overall Survival for Refractory mCRC
FEATURING
Arvind Dasari
- 16 views
- September 30, 2022
ecancer
ESMO 2022 on mBC Endpoints for Survival: rwPFS and TTNT
FEATURING
Chris Labaki
- 29 views
- September 28, 2022
ecancer
ESMO 2022 on the ELAINE Trial: Lasofoxifene vs. Fulvestrant for Locally Advanced or Metastatic ER+/HER2- BC
FEATURING
Matthew Goetz
- 176 views
- September 28, 2022
ecancer
ESMO 2022 Breast Cancer Highlights
FEATURING
Matteo Lambertini
- 626 views
- September 28, 2022
- 2
ecancer
ESMO 2022 on MONARCH 3 Interim Data: Abemaciclib + NSAI for HR+, HER2- aBC
FEATURING
Matthew Goetz
- 182 views
- September 28, 2022
- 1
ecancer
ESMO 2022 PEACE Study: Scientists Discover Mechanism of Action and an Actionable Inflammatory Axis for Air Pollution-Induced NSCLC
FEATURING
Charles Swanton
- 87 views
- September 27, 2022
ecancer
ESMO 2022 Results From a Phase 3 Study of 1L Atezo vs. Single-Agent Chemo in Pts With NSCLC
FEATURING
Siow Ming Lee
- 12 views
- September 27, 2022
ecancer
ESMO 2022 on EGFR Mutations in NSCLC: From Biomarker to Treatment Selections in Second Line
- 294 views
- September 27, 2022
ecancer
ESMO 2022: Atezolizumab Improves on Single-Agent Chemo for NSCLC Not Eligible for Platinum-Containing Regimen
FEATURING
Siow Ming Lee
- 135 views
- September 27, 2022